gms | German Medical Science

10. Kongress für Infektionskrankheiten und Tropenmedizin (KIT 2010)

Deutsche Gesellschaft für Infektiologie,
Deutsche AIDS-Gesellschaft,
Deutsche Gesellschaft für Tropenmedizin und Internationale Gesundheit,
Paul-Ehrlich-Gesellschaft für Chemotherapie

23.06. - 26.06.2010, Köln

Article

Send article

Analysis of HIV-1-specific CTL cross-reacting with Influenza A virus in a cohort of HIV-1 infected patients

Analyse von HIV-1-spezifischen CTL mit Kreuzreaktion zu Influenza A in einer Kohorte von HIV-1-infizierten Patienten

Meeting Abstract

Search Medline for

  • A. Hückelhoven - Universitätsklinik Erlangen, Medizinische Klinik 3, Erlangen, Germany
  • S. Bergmann - Universitätsklinik Erlangen, Medizinische Klinik 3, Erlangen, Germany
  • K. Eismann - Universitätsklinik Erlangen, Medizinische Klinik 3, Erlangen, Germany
  • S.M. Müller - Universitätsklinik Erlangen, Medizinische Klinik 3, Erlangen, Germany
  • J. Etschel - Universitätsklinik Erlangen, Medizinische Klinik 3, Erlangen, Germany
  • E.G. Harrer - Universitätsklinik Erlangen, Medizinische Klinik 3, Erlangen, Germany
  • T. Harrer - Universitätsklinik Erlangen, Medizinische Klinik 3, Erlangen, Germany
  • Kompetenznetzwerk HIV/AIDS

10. Kongress für Infektionskrankheiten und Tropenmedizin (KIT 2010). Köln, 23.-26.06.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. DocP155

doi: 10.3205/10kit209, urn:nbn:de:0183-10kit2090

Published: June 2, 2010

© 2010 Hückelhoven et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

Background: Recently, it has been shown that HLA-A2 restricted HIV-1-specific CTL recognizing the p17-epitope SL9 (SLYNTVATL) may cross-react with the influenza matrix epitope IMP (GILGFVFTL; Acierno et al., J translational Med, 2003) that is a dominant influenza epitope in HLA-A2 positive patients. So far, the prevalence of IMP-crossreacting HIV-1-specific CTL in larger HIV-1 infected patient cohorts is unknown and there are no data yet, whether SL9/IMP-cross-reactive CTL influences the course of HIV-1 infection.

Methods: We stimulated PBMC from 108 HLA A2 positive, HIV-1 infected patients (102 on antiretroviral therapy, 6 without therapy) in vitro with the HIV-1 p17 peptide SL9 and the influenza matrix protein peptide IMP. Outgrowing cell lines were analyzed regarding cross-reactivity between SL9 and IMP, peptide avidities and recognition of viral variants in у-IFN-Elispot assays.

Results: We could detect SL9-specific CTL in 58 patients and IMP-specific CTL in 65 patients. Outgrowing SL9-specific CTL lines cross-reacted to SL9 in 34 patients and outgrowing IMP-specific CTL lines to SL9 in 29 patients. Patients with cross-recognition of IMP and SL9 had a tendency of lower viral loads prior to starting antiretroviral therapy, but the differences were not significant (p=0.062, Man-Whitney-U-Test).

Conclusion: A significant proportion of HLA A2-positive patients have HIV-1 p17-specific CTL cross-reacting with a dominant IMP epitope. So far, we could not detect a significant influence of the presence of SL9/IMP-crossreacting CTL on the course of HIV-1 infection. Further studies are needed to assess whether SL9/IMP-cross-reactive CTL may lower the risk of transmission in HIV-1 exposed uninfected subjects and whether they may reduce the risk of developing symptomatic influenza A infection in HIV-1 infected patients.